New obesity drug SRSD384 enters human testing
NCT ID NCT07557355
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new injectable drug called SRSD384 in 78 overweight or obese adults. In the first part, participants receive a single dose of SRSD384 alone. In the second part, they receive SRSD384 combined with another weight-loss drug, tirzepatide. The main goal is to check safety and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SRSD384 injection
- What this could lead to
- If successful, this could point toward a new weight-loss treatment option for people with obesity, possibly combined with existing drugs like tirzepatide.
- What could go wrong
- This is an early-phase trial with only 78 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show meaningful weight loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NovaTrials
Charlestown, New South Wales, 2290, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can patients power their own obesity research?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?